AMAN U. BUZDAR, M.D.; GIUSEPPE FRASCHINI, M.D.; GEORGE R. BLUMENSCHEIN, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: Aminoglutethimide has been increasingly used in the treatment of hormonally responsive breast cancer instead of surgical adrenalectomy or hypophysectomy. The common side effects of the drug include skin rash and central-nervous-system side effects (lethargy, ataxia, and dizziness). These side effects are usually transient and rarely require discontinuation of the therapy. Hematotoxicity has been reported in few patients (1, 2), but the magnitude of this side effect has been emphasized in earlier publications. We would like to report our experience with three patients who developed severe, unexcepted, hematologic complications during treatment with aminoglutethimide. At our institution, 163 patients
BUZDAR AU, FRASCHINI G, BLUMENSCHEIN GR. Hematologic Adverse Effects of Aminoglutethimide. Ann Intern Med. ;100:159. doi: 10.7326/0003-4819-100-1-159_1
Download citation file:
Published: Ann Intern Med. 1984;100(1):159.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use